Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Acute myeloid leukemia, First remission, Acute lymphocytic leukemia, Acute leukemia, Second remission, Early relapse, Partial remission, Accelerated phase, Blast-crisis, Chronic myelogenous leukemia, Chronic phase, Recurrent malignant lymphoma, Refractory malignant lymphoma, Hodgkin's disease, Multiple myeloma., Chronic lymphocytic leukemia, Myeloproliferative disorder, Polycythemia vera, Myelofibrosis, Severe aplastic anemia
Eligibility Criteria
Inclusion Criteria:
Patients with the following diseases:
- Acute myeloid or lymphocytic leukemia in first remission at standard or high-risk for recurrence.
- Acute leukemia in greater than or equal to second remission, or with early relapse, or partial remission.
- Chronic myelogenous leukemia in accelerated phase or blast-crisis.
- Chronic myelogenous leukemia in chronic phase
- Recurrent or refractory malignant lymphoma or Hodgkin's disease
- Multiple myeloma.
- Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
- Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
- Severe aplastic anemia after failure of immunosuppressive therapy.
- Age 10-65 years.
- Zubrod performance status less than or equal to 2.
- Adequate cardiac and pulmonary function. Patients with decreased LVEF < 40% or DLCO < 50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol.
- Patient or guardian able to sign informed consent.
Exclusion Criteria:
- Life expectancy is severely limited by concomitant illness.
- Serum creatinine greater than 1.5 mg/dL or Creatinine Clearance less than 50 ml/min .
- Serum bilirubin greater than or equal to 2.0 mg/dl, SGPT greater than 3 x upper limit of normal
- Evidence of chronic active hepatitis or cirrhosis
- HIV-positive
- Patient is pregnant
Sites / Locations
- University of Illinois at Chicago Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Arm 1
Arm 2
All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.